Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and more
endpts.com·Apr 25, 2026
The Endpoints Weekly highlights significant developments in the biopharma sector, including Sanofi's reevaluation of its immunology strategy, Lilly's acquisition of an in vivo CAR-T biotech, and RevMed's notable advancements in cancer treatment.
The content provided does not offer a specific insight relevant to the reader's interests in healthtech, biotech, digital health, telemedicine, AI drug discovery, or related fields. If you are tracking investment signals, you might want to explore Lilly's acquisition of an in vivo CAR-T biotech as it could indicate strategic movements in the biotech sector.